Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-APRESOLINE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases c GMP via NO).
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.
250 mg orally twice daily
Reserpine: ~50-100 hours (biphasic; terminal phase 4.5-11 days due to enterohepatic circulation and tissue binding). Hydralazine: 2-8 hours (rapid acetylators 30-50 min, slow acetylators 2-8 hours); longer in renal impairment.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Reserpine: hydrolyzed in gut, metabolites excreted in urine. Hydralazine: N-acetylation via NAT2.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Reserpine: <1% unchanged in urine; extensive hepatic metabolism followed by renal and fecal excretion. Hydralazine: 80-90% renal; 10% fecal; 1-2% unchanged in urine; polymorphic acetylation (rapid/slow acetylators) affects clearance.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Reserpine: ~96% (bound to albumin and α1-acid glycoprotein). Hydralazine: 85-90% (primarily albumin; also binds to α1-acid glycoprotein and lipoproteins).
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Reserpine: ~8-10 L/kg (extensive tissue binding, especially adipose and brain). Hydralazine: 1.5-8 L/kg (increases with hypertension; reflects high tissue distribution).
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Reserpine: 5-30% oral (extensive first-pass metabolism; variable). Hydralazine: 30-50% oral (slow acetylators have higher bioavailability due to reduced first-pass acetylation; rapid acetylators 10-30%).
70-90% (oral); 100% (IV).
GFR <30 m L/min: Use with caution; reduce hydralazine component by 50%. GFR 30-50 m L/min: No adjustment needed for hydralazine; reserpine use contraindicated if severe renal impairment.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: No adjustment. Child-Pugh B: Reduce hydralazine dose by 50%. Child-Pugh C: Contraindicated due to risk of encephalopathy from reserpine and hepatotoxicity.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Weight-based: 0.01 mg/kg reserpine and 2.5 mg/kg hydralazine per day orally, divided into 1-2 doses. Maximum: reserpine 0.25 mg/day, hydralazine 50 mg/day.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at half the adult dose (1 tablet every other day) due to increased sensitivity to hypotension and CNS depression. Monitor for orthostatic hypotension and electrolyte imbalances.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Reserpine may cause depression, peptic ulcer, or arrhythmias.,Hydralazine may cause drug-induced lupus, peripheral neuritis, or orthostatic hypotension.,Monitor for hypotension and renal impairment.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to reserpine or hydralazine,Active peptic ulcer,Ulcerative colitis,Depression, especially with suicidal tendencies,Coronary artery disease (hydralazine may cause tachycardia)
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products, soy sauce, beer, wine) due to MAO inhibition from reserpine component; however, risk is lower than classical MAOIs. Avoid alcohol. Limit foods high in sodium to prevent fluid retention.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: Limited data; beta-blockers (reserpine component) associated with fetal bradycardia and growth restriction. Second/third trimester: Hydralazine and reserpine may cause neonatal hypotension, bradycardia, and hypothermia. Reserpine may increase risk of neonatal respiratory depression and nasal congestion.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Reserpine and hydralazine are excreted in breast milk. M/P ratio not well established. Reserpine may cause adverse effects in infants (diarrhea, nasal congestion). Hydralazine is considered compatible with caution. Avoid or use alternative antihypertensives with more safety data.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Pregnancy may alter pharmacokinetics of hydralazine (increased clearance) and reserpine (limited data). Dose adjustments may be needed based on blood pressure response. Avoid use in pregnancy if possible; no standard recommended dose adjustments.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Serpasil-Apresoline is a fixed-dose combination of reserpine and hydralazine, both antihypertensives with complementary mechanisms. Reserpine depletes catecholamines and serotonin, while hydralazine is a direct vasodilator. This combination is rarely used today due to poor tolerability (significant CNS depression, depression risk) and availability of better-tolerated agents. Monitor for orthostatic hypotension, bradycardia, and signs of depression. Avoid in patients with history of depression, peptic ulcer disease, or MAOI use. Abrupt withdrawal can cause hypertensive crisis.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Avoid alcohol and other central nervous system depressants.,Report any persistent fatigue, mood changes, or signs of depression.,May cause nasal congestion; do not use decongestants without consulting doctor.,Avoid prolonged sun exposure; may increase skin photosensitivity.,Contact doctor if you experience swelling of ankles/feet, weight gain, or shortness of breath.,Store at room temperature away from moisture and light.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-APRESOLINE vs ALDOCLOR-250, answered by our medical review team.
SERPASIL-APRESOLINE is a Antihypertensive Combination that works by Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases c GMP via NO).. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-APRESOLINE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-APRESOLINE is: 1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-APRESOLINE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-APRESOLINE is classified as Category C. First trimester: Limited data; beta-blockers (reserpine component) associated with fetal bradycardia and growth restriction. Second/third trimester: Hydralazine and reserpine may c. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.